Modified SpA Protein Binding Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current SpA-based reagents exhibit high binding affinity to both the Fab and Fc portions of immunoglobulins, which can be undesirable in certain applications, and there is a need for variants that offer improved specificity.
Innovation Solution
Development of modified SpA variants with altered amino acids at position 29, such as replacing glycine or alanine with other residues like leucine, lysine, or arginine, to reduce or increase binding specificity to the Fab portion while maintaining binding to the Fc portion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If SpA-based reagents are used for antibody purification, then high binding affinity to immunoglobulins is achieved, but binding specificity is reduced due to simultaneous binding to both Fab and Fc portions
Solution Approach 1:
The patent applies local quality by introducing specific amino acid substitutions at position 29 of the SpA binding domains (G29A, G29L, G29R, etc.) to create localized changes that differentially affect Fab versus Fc binding. This allows the protein to maintain overall binding capability while selectively reducing Fab portion binding, thereby improving binding specificity for Fc-containing antibodies.
Solution Approach 2:
The patent employs parameter changes by systematically varying the amino acid residue at position 29 across multiple SpA variants. By changing this single parameter (the identity of residue 29), the patent optimizes the balance between maintaining Fc binding affinity and reducing Fab binding, achieving improved binding specificity through controlled parameter modification.
2Manufacturing precision
If amino acid substitution at position 29 is performed to reduce Fab binding, then binding specificity is improved, but binding affinity to Fc portion may be affected
Solution Approach 1:
The patent systematically tests multiple amino acid substitutions (alanine, leucine, arginine, lysine, valine, isoleucine) at position 29 to identify variants that optimize the trade-off between Fab binding reduction and Fc binding maintenance. This parameter exploration allows selection of substitutions that achieve high specificity while preserving sufficient affinity for practical purification applications.
Solution Approach 2:
By focusing mutations exclusively at position 29 of the binding domains, the patent creates localized modifications that selectively impact Fab-Fc binding discrimination. This localized approach allows the rest of the protein structure to remain intact, preserving overall Fc binding capability while achieving specific Fab binding reduction.
3Manufacturing precision
If multiple SpA variants with different amino acids at position 29 are developed, then binding specificity can be optimized, but protein structure complexity increases
Solution Approach 1:
The patent maintains structural simplicity by limiting modifications to a single position (position 29) within the SpA binding domains. This localized mutation strategy allows multiple variants to be created with minimal structural changes, preserving the overall fold and domain architecture while achieving diverse binding specificities through single-residue variations.
Solution Approach 2:
The patent simplifies the complexity management by changing only one parameter (amino acid identity at position 29) rather than introducing multiple simultaneous modifications. This single-parameter variation approach enables systematic characterization of structure-function relationships and facilitates selection of optimal variants without compounding structural complexity.
Data Source
AI summary
The present invention relates to modified immunoglobulin-binding proteins, e.g., Staphylococcus protein A, having improved binding specificity for immunoglobulins and methods of making and using the same.